In vitro susceptibilities of Brucella melitensis isolates to eleven antibiotics

Annals of Clinical Microbiology and Antimicrobials

Volumn 5, Issue , 2006, Pages

  Turkmani, Aun ^a   Ioannidis, Alexandros ^a   Christidou, Athanasia ^a   Psaroulaki, Anna ^a   Loukaides, Feidias ^b   Tselentis, Yiannis ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b Veterinary Services of Cyprus   (Cyprus)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; ANTIBIOTIC AGENT; CIPROFLOXACIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; LEVOFLOXACIN; NORFLOXACIN; RIFAMPICIN; STREPTOMYCIN; TETRACYCLINE;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERIUM IDENTIFICATION; BACTERIUM ISOLATION; BRUCELLA MELITENSIS; BRUCELLOSIS; CONTROLLED STUDY; CYPRUS; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SYRIAN ARAB REPUBLIC;

ANIMALS; ANTI-BACTERIAL AGENTS; BRUCELLA MELITENSIS; BRUCELLOSIS; CYPRUS; DRUG RESISTANCE, BACTERIAL; GOAT DISEASES; GOATS; GREECE; HUMANS; MICROBIAL SENSITIVITY TESTS; MILK; SHEEP; SHEEP DISEASES; SYRIA;

EID: 33750308592     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-5-24     Document Type: Article

References (16)

1. Pappas G, Papadimitriou P, Akritidis N, Christou L, Tsianos EV: The new global map of human brucellosis. Lancet Infect Dis 2006, 6:91-99.
2. Bossi P, Tegnell A, Baka A, Van Loock F, Hendriks J, Werner A, Maidhof H, Gouvras G, Task Force on Biological and Chemical Agents Threats, Public Health Directorate, European Commission, Luxembourg. Bichat guidelines for the clinical management of brucellosis and bioterrorism-related brucellosis. Euro Surveill 2004, 15(9(12)):E15-16.
3. Pappas G, Akritidis N, Bosilkovski M, Tsianos E: Brucellosis. N Engl J Med 2005, 352:2325-2336.
4. Hall WH: Modern chemotherapy for brucellosis in humans. Rev Infect Dis 1991, 13(3):523-524.
5. Garcia-Rodriguez JA, Garcia-Sanchez JE, Trujillano I: Lack of effective bactericidal activity of new quinolones against Brucella spp. Antimicrob Agents Chemother 1991, 35:756-759.
6. Qadri SM, Halim MA, Ueno Y, Abumustafa FM, Postle AG: Antibacterial activity of azithromycin against Brucella melitensis. Chemotherapy 1995, 41(4):253-256.
7. Baykam N, Esener H, Ergonul O, Eren S, Celikbas AK, Dokuzoguz B: In vitro antimicrobial susceptibility of Brucella species. Intern J Antimicrob Agents 2004, 23:405-407.
8. Lopez-Merino A, Contreras-Rodriguez A, Migranas-Ortiz R, Orrantia-Gradin R, Hernandez-Oliva GM, Guttierrez-Rubio AT, Cardenosa O: Susceptibility of Mexican brucella isolates to moxifloxacin, ciprofloxacin and other antimicrobials used in the treatment of human brucellosis. Scand J Infect Dis 2004, 36:636-638.
9. National Committee for Clinical Laboratory Standards: Performance standards for antimicrobial susceptibility testing. In Eighth informational supplement NCCLS document M 100-S8 Volume 18. Wayne, PA; 1998.
10. Marianelli C, Ciuchini F, Tarantino M, Pasquali P, Adone R: Genetic bases of the rifampin resistance phenotype in Brucella spp. J Clin Microbiol 2004, 42:5439-5443.
11. Rubinstein E, Lang R, Shasha B, Hagar B, Diamanstein L, Joseph G, Anderson M, Harrison K: In vitro susceptibility of Brucella melitensis to antibiotics. Antimicrob Agents Chemother 1991, 35:1925-1927.
12. Akova M, Uzun O, Akalin HE, Hayran M, Unal S, Gur D: Quinolones in the treatment of human brucellosis: comparative trial of ofloxacin-rifampin versus doxycycline-rifampin. J Antimicrob Chemother 1993, 37:1831-1834.
13. Gur D, Kocagoz S, Akova M, Unal S: Comparison of E test to Microdilution for determining of in vitro activities of antibioticsagainst Brucella melitensis. Antimicrob Agents Chemother 1999, 43:2337.
14. Yamazham T, Aydemir S, Tunger A, Serter D, Gokengin D: Invitro activities of various antimicrobials against Brucella melitensis strains in the Aegean region in Turkey. Med Princ Pract 2005, 14(6):413-416.
15. Bodur H, Balaban N, Aksaray S, Yetener V, Akinci E, Colpan A, Erbay A: Biotypes and antimicrobial susceptibilities of Brucella isolates. Scand J Infect Dis 2003, 35(5):337-338.
16. Al Dakour S, Hagen RM, Nockler K, Tomaso H, Witting M, Scholz HC, Vergnaud G, Neubauer H: Failure of a short-term antibiotic therapy for human brucellosis using ciprofloxacin. A study on in vitro susceptibility of Brucella strains. Chemotherapy 2005, 51(6):352-356.